 This study will assess the effect of direct renin inhibition on nerve function in persons with diabetes using a double-blind, placebo-controlled randomized trial involving two treatment arms i.e., 1 30 participants enrolled and randomized to 300 mg of Aliskiren; 2 30 participants enrolled and randomized to placebo. 